


8-pCPT-2'-O-Me-cAMP-AM

Cat. No.:	HY-107544	
CAS No.:	1152197-23-3	
Molecular Formula:	C ₂₀ H ₂₁ ClN ₅ O ₈ PS	
Molecular Weight:	557.9	
Target:	PKA	
Pathway:	Stem Cell/Wnt	
Storage:	Pure form	-20°C 3 years
	In solvent	-80°C 6 months
		-20°C 1 month



BIOLOGICAL ACTIVITY

Description	8-pCPT-2'-O-Me-cAMP-AM is a cyclic AMP analogue, selectively activates Epac-Rap signaling pathway. 8-pCPT-2'-O-Me-cAMP-AM protects renal function by activating Epac from ischemia injury. 8-pCPT-2'-O-Me-cAMP-AM also stimulates insulin secretion by interaction with PKA pathway ^{[1][2]} .								
In Vitro	<p>8-pCPT-2'-O-Me-cAMP-AM (2.5 μM; 30 min) activates Epac and prevents adherens junction disassembly during hypoxia (60 min)^[1].</p> <p>8-pCPT-2'-O-Me-cAMP-AM can cross the plasma membrane and is able to alter diverse cellular functions that include Rap1 GTPase activity, PKB, and ERK1/2 protein kinase activity, phospholipase C activity, Ca²⁺ signaling, ion channel activity, exocytosis, cell adhesion, and gene expression^[2].</p> <p>8-pCPT-2'-O-Me-cAMP-AM stimulates insulin secretion with dose-dependent and glucose metabolism-dependent (0.1 or 1.11 mM) actions^[2].</p> <p>8-pCPT-2'-O-Me-cAMP-AM (20 μM) activates the cAMP reporter Epac1-camps, while 8-pCPT-2'-O-Me-cAMP doesn't in INS-1 cells^[2].</p> <p>8-pCPT-2'-O-Me-cAMP-AM (0.3-3.0 μM; 0-300 sec) activates Epac1-camps in a dose- and time-dependent manner in high throughput assay^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>8-pCPT-2'-O-Me-cAMP-AM (intrarenal injection;) activates renal Rap1 and likely is caused by activation of Epac in the tubular epithelium^[1].</p> <p>8-pCPT-2'-O-Me-cAMP-AM preserves renal function by Epac activation and reduces tubular epithelial-cell stress during ischemia^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="border: none;">Animal Model:</td> <td>IR injured mouse model^[1]</td> </tr> <tr> <td style="border: none;">Dosage:</td> <td>1.45 mM</td> </tr> <tr> <td style="border: none;">Administration:</td> <td>Intrarenal injection; mice were sacrificed at 24, 48, or 72 hours after ischemia</td> </tr> <tr> <td style="border: none;">Result:</td> <td>Protected renal injury during ischemia.</td> </tr> </table>	Animal Model:	IR injured mouse model ^[1]	Dosage:	1.45 mM	Administration:	Intrarenal injection; mice were sacrificed at 24, 48, or 72 hours after ischemia	Result:	Protected renal injury during ischemia.
Animal Model:	IR injured mouse model ^[1]								
Dosage:	1.45 mM								
Administration:	Intrarenal injection; mice were sacrificed at 24, 48, or 72 hours after ischemia								
Result:	Protected renal injury during ischemia.								

REFERENCES

- [1]. Stokman G, et al. Epac-Rap signaling reduces cellular stress and ischemia-induced kidney failure. *J Am Soc Nephrol*. 2011 May;22(5):859-72.
- [2]. Chepurny OG, et al. Enhanced Rap1 activation and insulin secretagogue properties of an acetoxymethyl ester of an Epac-selective cyclic AMP analog in rat INS-1 cells: studies with 8-pCPT-2'-O-Me-cAMP-AM. *J Biol Chem*. 2009 Apr 17;284(16):10728-36.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA